Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function
Authors:
- Jerri M. RookJRJerri M. Rook
- Paige N. VinsonPVPaige N. Vinson
- Hyekyung P. ChoHCHyekyung P. Cho
- Emily DaysEDEmily Days
- Y. ZhouYZY. Zhou
- Alice L. RodriguezARAlice L. Rodriguez
- Hilde LavreysenHLHilde Lavreysen
- Shaun R. StaufferSSShaun R. Stauffer
- Colleen M. NiswenderCNColleen M. Niswender
- Zixiu XiangZXZixiu Xiang
- J. Scott DanielsJDJ. Scott Daniels
- 1 February 2012
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 81 (2) , 120-133
Abstract
Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have emerged as an exciting new approach for the treatment of schizophrenia and other central nervous system (CNS) disorders. Of interest, some mGlu5 PAMs act as pure PAMs, only potentiating mGlu5 responses to glutamate whereas others [allosteric agonists coupled with PAM activity (ago-PAMs)] potentiate responses to glutamate and have intrinsic allosteric agonist activity in mGlu5-expressing cell lines. All mGlu5 PAMs previously shown to have efficacy in animal models act as ago-PAMs in cell lines, raising the possibility that allosteric agonist activity is critical for in vivo efficacy. We have now optimized novel mGlu5 pure PAMs that are devoid of detectable agonist activity and structurally related mGlu5 ago-PAMs that activate mGlu5 alone in cell lines. Studies of mGlu5 PAMs in cell lines revealed that ago-PAM activity is dependent on levels of mGlu5 receptor expression in human embryonic kidney 293 cells, whereas PAM potency is relatively unaffected by levels of receptor expression. Furthermore, ago-PAMs have no agonist activity in the native systems tested, including cortical astrocytes and subthalamic nucleus neurons and in measures of long-term depression at the hippocampal Schaffer collateral-CA1 synapse. Finally, studies with pure PAMs and ago-PAMs chemically optimized to provide comparable CNS exposure revealed that both classes of mGlu5 PAMs have similar efficacy in a rodent model predictive of antipsychotic activity. These data suggest that the level of receptor expression influences the ability of mGlu5 PAMs to act as allosteric agonists in vitro and that ago-PAM activity observed in cell-based assays may not be important for in vivo efficacy.Keywords
This publication has 43 references indexed in Scilit:
- Metabotropic glutamate receptors as therapeutic targets for schizophreniaNeuropharmacology, 2012
- Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffoldBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic ActivityMolecular Pharmacology, 2010
- Metabotropic Glutamate Receptors: Physiology, Pharmacology, and DiseaseAnnual Review of Pharmacology and Toxicology, 2010
- Discovery of Molecular Switches That Modulate Modes of Metabotropic Glutamate Receptor Subtype 5 (mGlu5) Pharmacology in Vitro and in Vivo within a Series of Functionalized, Regioisomeric 2- and 5-(Phenylethynyl)pyrimidinesJournal of Medicinal Chemistry, 2009
- mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial LearningNeuropsychopharmacology, 2009
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004
- Priming of long-term potentiation induced by activation of metabotropic glutamate receptors coupled to phospholipase CHippocampus, 1998